Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 14/20 | 0.73 |
| ▸ | F2 | P00734 | 9/20 | 0.71 |
| ▸ | KLK1 | P06870 | 3/20 | 0.63 |
| ▸ | PLG | P00747 | 1/20 | 0.63 |
| ▸ | F11 | P03951 | 1/20 | 0.63 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.63 |
| ▸ | CTRL | P40313 | 1/20 | 0.63 |
| ▸ | CTRB2 | Q6GPI1 | 1/20 | 0.63 |
| ▸ | CTRC | Q99895 | 1/20 | 0.63 |
| ▸ | F10 | P00742 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18040001 | 0.92 | KLKB1 (0.70) | KLKB1F2KLK1PLGF11 | |
| SCHEMBL18039766 | 0.92 | KLKB1 (0.70) | KLKB1F2KLK1PLGF11 | |
| SCHEMBL18039919 | 0.91 | KLKB1 (0.69) | KLKB1F2KLK1PLGF11 | |
| SCHEMBL29905438 | 0.86 | F2 (0.81) | KLKB1F2KLK1PLGF11 | |
| SCHEMBL29905827 | 0.85 | KLKB1 (0.78) | KLKB1F2KLK1PLGF11 | |
| SCHEMBL18039815 | 0.85 | KLKB1 (0.78) | KLKB1F2KLK1PLGF11 | |
| SCHEMBL20506150 | 0.84 | KLKB1 (1.00) | KLKB1F2KLK1PLGF11 | |
| SCHEMBL20506397 | 0.83 | F2 (1.00) | KLKB1F2KLK1PLGF11 | |
| SCHEMBL29905897 | 0.83 | F2 (1.00) | KLKB1F2KLK1PLGF11 | |
| SCHEMBL29905946 | 0.83 | F2 (0.77) | KLKB1F2KLK1PLGF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3261639-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INT CORPORATION (US) | 2022-08-24 | — | — | EP | claimed |
| EP-3261639-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INT CORPORATION (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20200109132-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2020-04-09 | — | — | US | disclosed |
| US-20180237421-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2018-08-23 | — | — | US | disclosed |
| EP-3261639-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | Verseon Corporation (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016138532-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON CORPORATION (US) | 2016-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109132-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, SERPINE1 | KLKB1 9/4885F2 30/4885KLK1 13/4885 |
| US-20180237421-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, SERPINE1 | KLKB1 9/4885F2 30/4885KLK1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.